Insider Transactions in Q3 2022 at Arcutis Biotherapeutics, Inc. (ARQT)

Date	Insider	Transaction	Ownership Type	Shares Traded	Value / Price
Sep 16 2022	Scott L Burrows Chief Financial Officer	BUY Exercise of conversion of derivative security	Direct	5,000 +11.05%	$5,000 $1.68 P/Share
Sep 07 2022	Todd Franklin Watanabe Director	SELL Open market or private sale	Direct	1,000 -0.26%	$21,000 $21.51 P/Share
Aug 15 2022	Howard G. Welgus Director	SELL Open market or private sale	Direct	6,000 -3.33%	$144,000 $24.8 P/Share
Aug 05 2022	Frazier Life Sciences Viii, L.P. > 10% Shareholder	BUY Open market or private purchase	Direct	250,000 +2.8%	$5,000,000 $20.0 P/Share
Aug 05 2022	Todd Franklin Watanabe Director	SELL Open market or private sale	Direct	2,500 -0.38%	$60,000 $24.74 P/Share
Aug 05 2022	Todd Franklin Watanabe Director	BUY Exercise of conversion of derivative security	Direct	2,500 +0.38%	$2,500 $1.68 P/Share
Jul 18 2022	Howard G. Welgus Director	SELL Open market or private sale	Direct	6,000 -3.22%	$144,000 $24.4 P/Share
Jul 08 2022	David W Osborne Chief Technical Officer	SELL Open market or private sale	Direct	2,197 -0.85%	$54,925 $25.41 P/Share
Jul 08 2022	Todd Franklin Watanabe Director	SELL Open market or private sale	Direct	13,500 -0.68%	$337,500 $25.27 P/Share
Jul 08 2022	Todd Franklin Watanabe Director	BUY Exercise of conversion of derivative security	Direct	7,087 +1.06%	$7,087 $1.68 P/Share
Jul 06 2022	Todd Franklin Watanabe Director	SELL Open market or private sale	Direct	1,000 -0.15%	$22,000 $22.07 P/Share

Receive a notification when an Institution or Guru buys or sells ARQT shares.

Notify only if

Value

Get notified when an Arcutis Biotherapeutics, Inc. insider buys or sells ARQT shares.

Notify only if

Operation

Value

Type

Receive news related to Arcutis Biotherapeutics, Inc.